首页 | 本学科首页   官方微博 | 高级检索  
检索        

润燥止痒胶囊联用组胺H1受体拮抗剂治疗老年皮肤瘙痒症的Meta分析
引用本文:石娴,邹爱玲,石年,付曼妮,解翠林.润燥止痒胶囊联用组胺H1受体拮抗剂治疗老年皮肤瘙痒症的Meta分析[J].现代药物与临床,2018,41(2):314-321.
作者姓名:石娴  邹爱玲  石年  付曼妮  解翠林
作者单位:鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)皮肤科, 湖北 黄石 435000,鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)皮肤科, 湖北 黄石 435000,鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)皮肤科, 湖北 黄石 435000,鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)皮肤科, 湖北 黄石 435000,鄂东医疗集团黄石市中心医院(湖北理工学院附属医院)皮肤科, 湖北 黄石 435000
基金项目:黄石市医药卫生科研指导项目[黄卫生计生通(2016)-270-14]
摘    要:目的 系统评价润燥止痒胶囊联用组胺H1受体拮抗剂治疗老年皮肤瘙痒症的临床疗效和安全性,为临床推广提供理论依据。方法 计算机检索PubMed、Medline、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)、维普中文科技期刊数据库(VIP)、万方数据库,收集润燥止痒胶囊联用组胺H1受体拮抗剂与单用组胺H1受体拮抗剂治疗老年皮肤瘙痒症临床随机对照研究,采用RevMan 5.2软件进行Meta分析。结果 共纳入18项研究,2 003例患者。Meta分析结果显示,与单用组胺H1受体拮抗剂,润燥止痒胶囊联用组胺H1受体拮抗剂能显著提高的临床有效率RR=1.45,95% CI (1.36,1.54),P<0.01],降低瘙痒程度评分MD=-2.83,95% CI (-3.51,-2.15),P<0.01]、瘙痒持续时间MD=-2.14,95% CI (-2.49,-1.79),P<0.01]、瘙痒发作频率MD=-2.39,95% CI (-2.81,-1.96),P<0.01]、瘙痒面积MD=-1.60,95% CI (-1.94,-1.26),P<0.01]和继发皮损评分MD=-1.87,95% CI (-2.48,-1.27),P<0.01]和ADR发生率RR=0.67,95% CI (0.52,0.88),P<0.01]。结论 润燥止痒胶囊联用组胺H1受体拮抗剂治疗老年皮肤瘙痒症的临床疗效优于单用组胺H1受体拮抗剂。

关 键 词:润燥止痒胶囊  组胺H1受体拮抗剂  老年皮肤瘙痒症  Meta分析
收稿时间:2017/9/22 0:00:00

Meta-analysis of Runzao Zhiyang Capsule combined with histamine H1 receptor antagonists in treatment of senile skin pruritus
SHI Xian,ZOU Ailing,SHI Nian,FU Manni and XIE Cuilin.Meta-analysis of Runzao Zhiyang Capsule combined with histamine H1 receptor antagonists in treatment of senile skin pruritus[J].Drugs & Clinic,2018,41(2):314-321.
Authors:SHI Xian  ZOU Ailing  SHI Nian  FU Manni and XIE Cuilin
Institution:Department of Dermatology & STD in Huangshi Central Hospital, Edong Health Care Group, Huangshi 435000, China,Department of Dermatology & STD in Huangshi Central Hospital, Edong Health Care Group, Huangshi 435000, China,Department of Dermatology & STD in Huangshi Central Hospital, Edong Health Care Group, Huangshi 435000, China,Department of Dermatology & STD in Huangshi Central Hospital, Edong Health Care Group, Huangshi 435000, China and Department of Dermatology & STD in Huangshi Central Hospital, Edong Health Care Group, Huangshi 435000, China
Abstract:Objective To systematically review the efficacy and safety of Runzao Zhiyang Capsule combined with Histamine H1 receptor antagonists in treatment of senile skin pruritus, to provide theoretical basis for clinical popularization.Methods Databases including PubMed, Medline, CNKI, VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about Runzao Zhiyang Capsule combined with Histamine H1 receptor antagonists vs Histamine H1 receptor antagonists alone in treatment of senile skin pruritus. Then Meta-analysis was conducted by RevMan 5.2 software.Results Total of 18 RCTs, 2003 patients were included. Meta-analysis showed that, compared to histamine H1 receptor antagonists alone, Runzao Zhiyang Capsule combined with histamine H1 receptor antagonists could improved clinical effective rateRR=1.45, 95% CI(1.36, 1.54), P< 0.01], lower the degree of itching scoreMD=-2.83, 95% CI(-3.51, -2.15), P< 0.01], duration of itchingMD=-2.14, 95% CI(-2.49, -1.79), P< 0.01], itching frequencyMD=-2.39, 95% CI(-2.81, -1.96), P< 0.01], itching areaMD=-1.60, 95% CI(-1.94, -1.26), P< 0.01], secondary skin lesionsMD=-1.87, 95% CI(-2.48, -1.27), P< 0.01] and rate of ADRRR=0.67, 95% CI(0.52, 0.88), P< 0.01].Conclusion Current evidence shows that the clinical curative effect of Runzao Zhiyang Capsule combined with histamine H1 receptor antagonists in treatment of senile skin pruritus much better than histamine H1 receptor antagonists alone.
Keywords:Runzao Zhiyang Capsule  histamine H1 receptor antagonists  senile skin pruritus  Meta-analysis
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号